门诊局麻下软件辅助MRI-TRUS融合引导经会阴前列腺穿刺的安全性与有效性
本研究纳入203例PI-RADS>2患者,在门诊局麻下用融合软件行经会阴前列腺穿刺,总体及临床显著癌检出率分别为73.5%和60.1%,PI-RADS 3/4/5病灶临床显著癌检出率依次为23.2%、66.1%、89.1%,操作耐受好、并发症少。
要点
- PI-RADS 5病灶临床显著癌检出率达89.1%,应优先靶向穿刺。
- PI-RADS 3病灶临床显著癌检出率仅23.2%,需结合PSA等综合决策。
- 门诊局麻下经会阴融合穿刺安全可行,感染并发症约1%。
核心结论
- MRI-TRUS融合软件引导经会阴靶向穿刺在门诊局麻下具有较高的总体癌和临床显著癌检出率,且耐受性好、并发症发生率低。
研究设计与样本
- 单中心前瞻性纳入2021年3月至2022年5月203例PI-RADS评分>2的男性患者,在门诊局麻下使用专用融合软件行经会阴前列腺穿刺,共靶向223个可疑病灶。
- 主要结局为(临床显著)癌检出率,次要结局为操作时间、患者不适感和并发症发生率。
诊断标准与关键数值
- 总体癌检出率为73.5%,临床显著癌检出率为60.1%。
- PI-RADS 3病灶的癌检出率为46.4%、临床显著癌检出率为23.2%;PI-RADS 4为78.5%、66.1%;PI-RADS 5为93.5%、89.1%。
临床应用与阅片要点
- 对于PI-RADS 4-5病灶,融合靶向穿刺临床显著癌检出率高,可优先安排靶向穿刺。
- PI-RADS 3病灶临床显著癌检出率较低,报告时应提示结合临床及PSA等指标综合评估。
- 门诊局麻下操作安全可行,但需注意 vasovagal 反应(2%)和感染并发症(1%)的预防与识别。
局限性
- 单中心研究,样本量203例,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate diagnostic accuracy, safety, and efficiency of an MRI-TRUS fusion-guided transperineal prostate biopsy method in an outpatient setting under local anaesthesia.
METHODS: Patients undergoing transperineal prostate biopsy were included from March 2021 to May 2022. Biopsies were performed under local anaesthesia in an outpatient setting, using specialised fusion software. Primary outcome was (clinically significant) cancer detection rate. Secondary outcomes were procedure time, patient discomfort during the procedure and complication rate.
RESULTS: We included 203 male patients (69 years +-SD 8.2) with PI-RADS score > 2. In total 223 suspicious lesions were targeted. Overall cancer detection rate and clinically significant cancer detection rate were 73.5% and 60.1%, respectively. (Clinically significant) cancer detection rates in PI-RADS 3, 4 and 5 lesions were 46.4% (23.2%), 78.5% (66.1%) and 93.5% (89.1%), respectively. Mean duration of the procedure including fusion, targeted and systematic biopsies was 22.5 min. Patients rated injection of local anaesthesia on a numeric pain rating scale on average 3.7/10 (SD 2.09) and biopsy core sampling 1.6/10 (SD 1.65). No patient presented with acute urinary retention on follow-up consultation. Two (1%) patients presented with infectious complications. Four (2%) patients experienced a vasovagal reaction.
CONCLUSION: Transperineal targeted biopsy with MRI-TRUS fusion software has high overall and clinically significant cancer detection rates. The method is well tolerated under local anaesthesia and in an outpatient setting.
引用
- De Vulder, Slots, Geldof, et al. Safety and efficacy of software-assisted MRI-TRUS fusion-guided transperineal prostate biopsy in an outpatient setting using local anaesthesia. Abdom Radiol (NY). 2022. PMID: 36399208. doi:10.1007/s00261-022-03745-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。